Home » Stocks » AGIO

Agios Pharmaceuticals, Inc. (AGIO)

Stock Price: $48.10 USD -2.19 (-4.35%)
Updated Feb 26, 2021 12:56 PM EST - Market open
Market Cap 3.49B
Revenue (ttm) 203.20M
Net Income (ttm) -327.37M
Shares Out 69.00M
EPS (ttm) -4.91
PE Ratio n/a
Forward PE 7.86
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $48.10
Previous Close $50.29
Change ($) -2.19
Change (%) -4.35%
Day's Open 47.63
Day's Range 46.57 - 49.85
Day's Volume 593,873
52-Week Range 27.77 - 58.93

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 3 hours ago

Agios' (AGIO) loss meets estimates in the fourth quarter of 2020 while revenues beat the same. Sale of leukemia drug, Tibsovo, rise both sequentially as well as year over year.

GlobeNewsWire - 5 hours ago

– In Partnership with the Sickle Cell Community Consortium, Agios Works to Address Educational Resource Gaps Caused by COVID-19 for Students with Sickle Cell Disease –

GlobeNewsWire - 1 day ago

– Strong Commercial Execution for Second Full Year of TIBSOVO ® with Fourth Quarter Net Revenue of $39.1M and $121.1M for Full Year 2020 –

GlobeNewsWire - 3 days ago

CAMBRIDGE, Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, to...

Zacks Investment Research - 1 week ago

Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 2 weeks ago

CAMBRIDGE, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, t...

GlobeNewsWire - 4 weeks ago

– 37 Percent of Patients Treated with Mitapivat Achieved ≥33% Reduction in Transfusion Burden Compared to Individual Historical Transfusion Burden Standardized to 24 Weeks (1-Sided p=0.0002) –

GlobeNewsWire - 1 month ago

– Supplemental New Drug Application Planned for Submission in Q1 2021 – – Supplemental New Drug Application Planned for Submission in Q1 2021 –

GlobeNewsWire - 1 month ago

– Company Expects to File for Regulatory Approval for Mitapivat for the Treatment of Adults with Pyruvate Kinase (PK) Deficiency in the U.S. in Q2 2021 and in the EU in Mid-2021 –

GlobeNewsWire - 1 month ago

CAMBRIDGE, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, to...

Seeking Alpha - 1 month ago

Agios recently sold off its oncology business to Servier for $2B ($1.8B in cash) creating a unique situation to buy a company with a strong drug development track record. With 2 drug approvals...

Zacks Investment Research - 2 months ago

Investors need to pay close attention to Agios (AGIO) stock based on the movements in the options market lately.

Zacks Investment Research - 2 months ago

Agios (AGIO) sells its oncology business unit to French company Servier for around $2 billion. The company plans to solely focus on developing treatments for genetically defined diseases.

The Motley Fool - 2 months ago

Agios' newly revamped business strategy is an extreme departure from the company's original mission, but it's a great deal for shareholders.

The Motley Fool - 2 months ago

Investors applauded the company's planned sale of its oncology portfolio.

24/7 Wall Street - 2 months ago

The announcement that Agios Pharmaceuticals Inc. (NASDAQ: AGIO) will be streamlining its portfolio sent shares sharply higher early Monday.

Market Watch - 2 months ago

Shares of Agios Pharmaceuticals Inc. soared 20.6% in premarket trading on Monday after the company said it is selling its oncology portfolio to Servier, a privately held French pharmaceutical ...

GlobeNewsWire - 2 months ago

– Agios to Dedicate All Resources to Advancing Mitapivat as a Potential Treatment for Three Initial Hemolytic Anemias and Building on its Scientific Expertise in Cellular Metabolism and PK Act...

GlobeNewsWire - 2 months ago

– Treatment with Mitapivat Induced Hemoglobin Increase of ≥1.0 g/dL in 6 of 11 (55%) Efficacy Evaluable Patients , Decreased Markers of Hemolysis, Reduced 2,3-DPG and Increased ATP –

Zacks Investment Research - 2 months ago

Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 2 months ago

Agios' (AGIO) phase III ACTIVATE study evaluating mitapivat for addressing PK deficiency in patients with no regular blood transfusions achieves the primary goal.

GlobeNewsWire - 2 months ago

CAMBRIDGE, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today ann...

GlobeNewsWire - 3 months ago

CAMBRIDGE, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today ann...

Zacks Investment Research - 3 months ago

The FDA confers an orphan drug status on Agios' (AGIO) pyruvate kinase-R activator mitapivat for addressing sickle cell disease. Stock climbs in after-hours trading.

GlobeNewsWire - 3 months ago

CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today an...

Zacks Investment Research - 3 months ago

Agios' (AGIO) earnings and revenues fall shy of estimates in the third quarter. The company lifts the lower end of 2020 sales guidance for its leukemia drug Tibsovo.

Seeking Alpha - 3 months ago

Agios Pharmaceuticals' (AGIO) CEO Jackie Fouse on Q3 2020 Results - Earnings Call Transcript

Benzinga - 3 months ago

  Shares of Agios Pharmaceuticals (NASDAQ:AGIO) were unchanged after the company reported Q3 results.

GlobeNewsWire - 3 months ago

– Third Quarter TIBSOVO® Net Revenue of $31.7 Million; Company Narrows 2020 TIBSOVO® Net U.S. Revenue Guidance to $113–115 Million –

GlobeNewsWire - 3 months ago

Company to Host Virtual Investor Event and Webcast on Tuesday, December 8, 2020 at 8:00 a.m. ET Company to Host Virtual Investor Event and Webcast on Tuesday, December 8, 2020 at 8:00 a.m. ET

GlobeNewsWire - 3 months ago

CAMBRIDGE, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today ann...

Zacks Investment Research - 3 months ago

Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 4 months ago

Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 4 months ago

CAMBRIDGE, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today an...

Seeking Alpha - 4 months ago

Agios: A Look At Mitapivat In Anaemia, Its Backup Indication

Zacks Investment Research - 4 months ago

Agios (AGIO) withdraws the regulatory filing for Tibsovo in Europe, which was developed to treat relapsed/refractory acute myeloid leukemia in adult patients with a susceptible IDH1 mutation.

Seeking Alpha - 4 months ago

Agios: A Look At TIBSOVO In CC Patients

GlobeNewsWire - 4 months ago

– Agios Continues to Advance Two Phase 3 Combination Trials of TIBSOVO ® in Newly Diagnosed AML Patients –

Zacks Investment Research - 4 months ago

Agios Pharmaceuticals (AGIO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

GlobeNewsWire - 5 months ago

– Supplemental New Drug Application Planned f or Submission in Q1 2021 –

GlobeNewsWire - 5 months ago

Andrew Hirsch to Depart Agios and Remain a Strategic Advisor through October 2020 Andrew Hirsch to Depart Agios and Remain a Strategic Advisor through October 2020  

Seeking Alpha - 5 months ago

Tibsovo sales, after weakness during launch, are ramping nicely.

Zacks Investment Research - 5 months ago

Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock?

GlobeNewsWire - 5 months ago

CAMBRIDGE, Mass., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today a...

GlobeNewsWire - 6 months ago

CAMBRIDGE, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today a...

Seeking Alpha - 6 months ago

Agios Pharmaceuticals, Inc. (AGIO) CEO Jacqualyn Fouse on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 7.75% and 5.62%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the st...

GlobeNewsWire - 6 months ago

– Second Quarter TIBSOVO® Net Revenue of $27.6 Million; Company Reiterates 2020 TIBSOVO® Net U.S. Revenue Guidance of $105–115 Million –

Zacks Investment Research - 7 months ago

Agios Pharmaceuticals (AGIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 7 months ago

CAMBRIDGE, Mass., July 16, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today ...

About AGIO

Agios Pharmaceuticals, a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of hematologic malignancies, solid tumors, and rare genetic diseases. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA, an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutatio... [Read more...]

Industry
Biotechnology
IPO Date
Jul 24, 2013
CEO
Jacqualyn Fouse
Employees
536
Stock Exchange
NASDAQ
Ticker Symbol
AGIO
Full Company Profile

Financial Performance

In 2020, AGIO's revenue was $203.20 million, an increase of 72.33% compared to the previous year's $117.91 million. Losses were -$327.37 million, -20.44% less than in 2019.

Financial Statements

Analyst Forecasts

According to 12 analysts, the average rating for AGIO stock is "Buy." The 12-month stock price forecast is 66.10, which is an increase of 37.42% from the latest price.

Price Target
$66.10
(37.42% upside)
Analyst Consensus: Buy